Grupo Español De Investigación En Cáncer De Ovario

This study tested whether adding the immunotherapy drug atezolizumab to standard chemotherapy and bevacizumab helps people with advanced, persistent, or recurrent cervical cancer live longer. About 410 participants received either the standard treatment or the standard plus atezo…

This study reviewed medical records of 51 people with ovarian, fallopian tube, or peritoneal cancer who took the drug rucaparib. Researchers wanted to see how well the drug works and what side effects occur in real-world settings, not just in controlled trials. The goal was to un…